Ranolazine is a novel anti-anginal agent acting through pharmacologic mechanism of inhibition of the
late phase of the inward sodium current. In addition, it is a potent inhibitor of rapid delayed rectifier
potassium currents, leading to prolongation of the QT interval. However, ranolazine has not yet described
to be associated with Torsade de Pointes despite its QT-prolonging effect. In this case report, we describe a
patient on ranolazine who developed Torsade de Pointes and discuss about the potential contribution of
ranolazine to the development of Torsade de Pointes.
Prolonged QT interval
Torsade de Pointes